ESC Congress 2019 - Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial

09.02.2019 - By ESC Cardio Talk

Download our free app to listen on your phone

With Roxana Mehran, The Mount Sinai Hospital - USA, Jan Steffel, University Hospital Zurich - Switzerland & Diana Gorog, University of Hertfordshire - UK

Link to paper: https://bit.ly/2lz0NfG

More episodes from ESC Cardio Talk